曼恩凯德生物医疗 MNKD 深 沪
等待开盘 08-25 09:30:00 美东时间
4.07
-0.080
-1.93%
华盛通- 最 高4.14
- 今 开4.13
- 成交量 281.19万股
- 最 低 4.06
- 昨 收 4.15
- 总市值 13.09亿
- 52周最高 6.51
- 市盈率 静 217.65
- 换手率 0.87%
- 52周最低 2.23
- 委 比 71.78%
- 总股本 3.22亿
- 历史最高 57.40
- 量 比 0.70
- 振 幅 1.93%
- 历史最低 0.666
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.
08-07 01:17
MannKind 2026年第二季度财报：营收增43%，费用扩张转为亏损
MannKind 2026年第二季度营收1.094亿美元，同比增长43%，稀释每股亏损0.06美元、净亏损1903万美元；Furoscix与合作收入推动增长，但商业化及融资成本加重亏损。
08-05 21:17
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration’s (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease. MannKind (MNKD) Jumps On FDA Approval Of F...
07-25 02:06
MannKind shares rise on announcing $50M private placement financing
Biopharmaceutical company MannKind Corporation (MNKD) announced that it has entered into a securities purchase agreement for a private placement expected to yield approximately $50 million in gross pr...
07-24 18:59
MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a pri...
07-24 18:37
MannKind Announces $50 Million Private Placement
MannKind Corporation announced a $50 million private placement with institutional investors, led by Frazier Life Sciences. Proceeds will fund general corporate purposes, including a $45 million contingent value rights payment triggered by the FDA approval of Furoscix ReadyFlow™. The company is selling 10,440,838 shares of common stock and pre-funded warrants for up to 2,412,632 shares at $3.89 and $3.88 per share, respectively. The securities are...
07-24 10:35
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
The U.S. FDA has approved Furoscix ReadyFlow (furosemide injection) for treating edema in adults with heart failure or chronic kidney disease. This innovative autoinjector delivers an 80 mg/mL dose in under 10 seconds, providing IV-equivalent diuretic effects and symptom relief within an hour. As the first subcutaneous furosemide autoinjector, it offers a convenient at-home treatment option, potentially reducing hospitalizations and improving pat...
07-24 10:30
